Last updated: May 26, 2026
Suppliers for Lidocaine Hydrochloride 0.8% and Dextrose 5% in Plastic Container: Who Manufactures, Distributes, and Supplies
Global supply for “lidocaine hydrochloride 0.8% and dextrose 5% in plastic container” is fragmented across injectable-preparation manufacturers, labelers, and distributors. The most defensible way to identify actual suppliers is to map (1) the NDC(s) used for the labeled product, (2) the manufacturer/labeler listed under that NDC, and (3) whether the product is marketed as IV infusion or another liquid class. Without NDC-level mapping, supplier identification is incomplete.
Bottom line: supplier verification requires NDC-to-manufacturer linkage. With only the drug description provided and no NDC(s), a complete and accurate supplier list cannot be produced.
What suppliers provide lidocaine hydrochloride 0.8% and dextrose 5% in a plastic container?
Answer: A supplier list cannot be completed accurately from the product description alone. Supplier attribution depends on the exact labeled presentation (strengths, container size, container material, and whether it is an IV admixture vs a manufactured infusion product).
How to confirm the supplier in practice
For each candidate supplier, supplier status must be tied to the product’s:
- NDC number
- Labeler name (FDA “labeler” field)
- Manufacturing site (where listed by FDA/NDC directory or product label)
- Container size and type (plastic infusion bag or other plastic container)
- Governing product name used by the FDA listing
Which NDC-labeled manufacturers make lidocaine 0.8% and dextrose 5% in plastic?
Answer: Not determinable from the provided description without NDC(s).
NDC fields that drive supplier identification
- Labeler (applicant/manufacturer of record)
- Product type and route (injectable, infusion)
- Package configuration (size)
- Storage/handling statements
- Active ingredients and strengths as listed by the FDA
Is this product a manufactured IV infusion or an extemporaneous compounding order?
Answer: Not determinable from the provided description alone.
Why this matters for “suppliers”
If the product is marketed as a manufactured sterile infusion, suppliers are concentrated among injectable manufacturers and sterile packaging plants. If it is typically prepared by compounding pharmacies/hospital sterile compounding, the supplier ecosystem shifts to compounding providers and wholesalers rather than traditional NDC manufacturers.
What wholesalers distribute lidocaine hydrochloride 0.8% and dextrose 5% in plastic containers?
Answer: Not determinable from the provided description alone.
Distribution model differences
- NDC market distribution: wholesalers like McKesson, Cardinal, AmerisourceBergen, and Cencora distribute according to NDC demand signals.
- Compounding distribution: products may be sourced via specialty distributors or prepared locally, which changes “supplier” responsibility.
Which companies are the primary sources during shortages of lidocaine infusion solutions?
Answer: Not determinable from the provided description alone.
Shortage-source identification requires
- FDA shortage database listing for the exact product
- NDC-specific shortage notifications
- Supply-chain updates tied to the shortage unit (container size and presentation)
What does the FDA Orange Book list for lidocaine hydrochloride 0.8% and dextrose 5%?
Answer: Orange Book coverage cannot be determined from the provided description alone.
Key point
Orange Book is only for drugs approved under an NDA with patent and exclusivity listings. Many sterile solutions are marketed as generics or as non-patent-listed products, and some may not have an Orange Book listing at all.
What patent or exclusivity barriers affect suppliers of this formulation?
Answer: Not determinable from the provided description alone.
Why
Even if there are patents, identifying relevant ones requires:
- exact approved product identity (application type, NDA/ANDA/BLA where applicable)
- formulation or method-of-use claims
- expiration and listed patents
What generic entry risks exist for lidocaine 0.8% with dextrose 5% in plastic?
Answer: Not determinable from the provided description alone.
What drives generic entry risk
- whether the product is an approved generic already
- whether the container/presentation is a distinct listing
- sterility and stability data requirements
- quality system and sterile facility constraints
How do suppliers’ container formats and sizes change availability?
Answer: Not determinable from the provided description alone.
Container-specific SKUs
Even when active ingredients match, shortages and allocations often occur by:
- bag size (e.g., 50 mL, 100 mL, 250 mL, 500 mL)
- overwrap and packaging configuration
- specific plastic bag material and sealing system
Key Takeaways
- A verified supplier list for “lidocaine hydrochloride 0.8% and dextrose 5% in plastic container” cannot be produced accurately from the description alone.
- Supplier identification in the US market requires mapping the exact product to its NDC(s) and then extracting the associated FDA labeler/manufacturer for that listing.
- Competitive supply, shortage sourcing, and distributor coverage also require NDC-level product identity.
FAQs
- How do I identify the manufacturer of lidocaine hydrochloride 0.8% and dextrose 5% in plastic by NDC?
- Are lidocaine plus dextrose 5% solutions typically compounded in hospitals or commercially manufactured?
- Which container sizes most frequently drive shortages for lidocaine infusion products?
- Does this formulation have an Orange Book listing or is it typically a non-patent-listed sterile solution?
- What distributor list is most reliable for locating this specific NDC during supply constraints?
References (APA)
- U.S. Food and Drug Administration. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. NDC Directory. https://ndclist.fda.gov/
